Page last updated: 2024-08-16

thalidomide and arsenic trioxide

thalidomide has been researched along with arsenic trioxide in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	33 (84.62)	29.6817
2010's	5 (12.82)	24.3611
2020's	1 (2.56)	2.80

Authors

Authors	Studies
Hussein, MA; Juturi, JV; Lieberman, I	1
Hussein, MA	1
List, AF	1
Anderson, KC; Cole, CE; Ryoo, JJ	1
Anderson, KC; Hayashi, T; Hideshima, T	1
Gisslinger, H; Kees, M	1
Mehta, J; Pichardo, D; Rosen, S; Singhal, S	1
Chen, SL	1
Gibson, AD; Klem, J; Price, N; Reddy, GK	1
Kaufman, J; Lonial, S	1
Alvi, MI; Buonamici, S; Candoni, A; Chaudary, NI; Galili, N; Gallegos, JA; Gezer, S; Imran, M; Li, D; Lisak, L; Mumtaz, M; Nucifora, G; Pervaiz, H; Raza, A; Reddy, P; Singer, J; Tahir, S; Venugopal, P	1
Bertola, A; Boccadoro, M; Bruno, B; Giaccone, L; Massaia, M; Palumbo, A; Rotta, M	1
Cardinale, G; Gervasi, F; Pagnucco, G	1
Chng, WJ; Lau, LG; Mow, BM; Yusof, N	1
Anderson, KC; Catley, L; Chauhan, D; Tai, YT	1
Saunders, G	1
Murakami, H	1
Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Nowak, D	1
Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R	1
Jin, J; Lu, J; Xu, WL	1
Hess, U	1
Hussein, MA; Kalmadi, SR	1
Jin, J; Lu, J	1
Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y	1
Dai, CW; Pei, MF; Shen, JK; Xu, YX; Zhang, GS; Zheng, WL	1
Takatoku, M	1
Fei, XM; Ge, Z; Li, JY; Lin, RF; Liu, P; Lu, H; Shen, WY; Wang, YR; Wu, YJ; Zhang, JF	1
Berenson, JR; Yellin, O	1
Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT	1
Gotlib, J; Greenberg, PL	1
Chan, GC; Sze, DM	1
Sekeres, MA	1
Gotlib, J; Oh, ST	1
Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D	1
Advani, A; Bejanyan, N; Chan, J; Jankowska, A; Kalaycio, M; Maciejewski, JP; Mooney, L; Raza, A; Saunthararajah, Y; Sekeres, MA; Tiu, RV	1
Guo, L; Hou, J; Shi, H; Wei, W; Zhang, Y; Zhou, F	1
Chahardouli, B; Ghavamzadeh, A; Mohammadi Kian, M; Mohammadi, S; Nikbakht, M; Rostami, S; Tavallaei, M; Zahedpanah, M	1
Bunce, CM; Drayson, MT; Khanim, FL	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

27 review(s) available for thalidomide and arsenic trioxide

Article	Year
Multiple myeloma: present and future. Current opinion in oncology, 2002, Volume: 14, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Oxides; Pamidronate; Thalidomide; Zoledronic Acid	2002
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome	2002
New approaches to the treatment of myelodysplasia. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome	2002
Novel therapies for multiple myeloma. Blood reviews, 2002, Volume: 16, Issue:3 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Enzyme Inhibitors; Estradiol; Humans; Multienzyme Complexes; Multiple Myeloma; Oxides; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts	2002
Novel therapies for multiple myeloma. British journal of haematology, 2003, Volume: 120, Issue:1 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Enzyme Inhibitors; Estradiol; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; NF-kappa B; Oxides; Phthalazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thalidomide	2003
Therapy strategies for multiple myeloma: current status. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous	2003
Recent developments and future directions in the treatment of multiple myeloma. Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:4 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts	2003
Multiple myeloma: the role of transplant and novel treatment strategies. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 4 Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous	2004
New drugs for treatment of multiple myeloma. The Lancet. Oncology, 2004, Volume: 5, Issue:7 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Diphosphonates; Enzyme Inhibitors; Estradiol; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thalidomide	2004
Targeting multiple myeloma cells and their bone marrow microenvironment. Annals of the New York Academy of Sciences, 2004, Volume: 1028 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide	2004
Targeted therapy in multiple myeloma. Cancer control : journal of the Moffitt Cancer Center, 2005, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide	2005
Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2005, Volume: 8, Issue:4 Topics: 2-Methoxyestradiol; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Proteasome Inhibitors; Receptor Protein-Tyrosine Kinases; Thalidomide	2005
Overview of drug therapy for multiple myeloma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:3 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide	2005
[New strategy for the treatment of multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning	2005
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Current pharmaceutical design, 2006, Volume: 12, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Oligonucleotides, Antisense; Oxides; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines; Rituximab; Thalidomide	2006
New treatments for multiple myeloma. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:14 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2005
[The plasma cell myeloma--molecular pathogenesis and target therapies]. Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors	2006
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta haematologica, 2006, Volume: 116, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2006
[Molecular targeting therapy for multiple myeloma]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A	2007
New drugs in multiple myeloma. Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:3 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2008
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thrombosis research, 2009, Volume: 123, Issue:5 Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism	2009
Novel biospecific agents for the treatment of myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network : JNCCN, 2003, Volume: 1, Issue:4 Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide	2003
Supplements for immune enhancement in hematologic malignancies. Hematology. American Society of Hematology. Education Program, 2009 Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; beta-Glucans; Child; Clinical Trials as Topic; Dietary Supplements; Digestive System Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Drugs, Chinese Herbal; Ganoderma; Hematologic Neoplasms; Herb-Drug Interactions; Humans; Immunologic Factors; Mice; Oxides; Phytotherapy; Plant Preparations; Polyporus; Thalidomide	2009
Arsenic trioxide as a treatment for myelodysplastic syndrome. Current hematologic malignancy reports, 2006, Volume: 1, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Salvage Therapy; Thalidomide; Transcription Factors	2006
Antiangiogenesis in myelodysplastic syndrome. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide	2011
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies. Blood cancer journal, 2022, 10-07, Volume: 12, Issue:10 Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin	2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

3 trial(s) available for thalidomide and arsenic trioxide

Article	Year
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leukemia research, 2008, Volume: 32, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Risk Factors; Thalidomide; Treatment Outcome; Tretinoin	2008
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer, 2012, Aug-15, Volume: 118, Issue:16 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Myelodysplastic-Myeloproliferative Diseases; Oxides; Primary Myelofibrosis; Thalidomide	2012
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes. Leukemia research, 2012, Volume: 36, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Oxides; Pilot Projects; Survival Analysis; Thalidomide; Treatment Outcome	2012

Other Studies

9 other study(ies) available for thalidomide and arsenic trioxide

Article	Year
[Targeted in therapies multiple myeloma]. Zhonghua nei ke za zhi, 2004, Volume: 43, Issue:2 Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2004
45th Annual Meeting of the American Society of Hematology December 6-9, 2003. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase	2004
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leukemia research, 2004, Volume: 28, Issue:8 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Lineage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Spleen; Thalidomide; Transcription Factors; Zinc Fingers	2004
[Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2006, Volume: 44, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Myelodysplastic Syndromes; Neoplasm Transplantation; Oxides; Random Allocation; Survival Rate; Thalidomide; Tumor Cells, Cultured	2006
[Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2006, Volume: 44, Issue:10 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Humans; I-kappa B Proteins; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Mitochondria; Myelodysplastic Syndromes; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide	2006
Refractory multiple myeloma treated with homoharringtonine: report of two cases. Annals of hematology, 2007, Volume: 86, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine	2007
[Effects of As2O3, dexamethasone and thalidomide on apoptosis and cytoplasmic [Ca2+] of myeloma cell line U266]. Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cytoplasm; Dexamethasone; Humans; Multiple Myeloma; Oxides; Thalidomide	2007
Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Current hematologic malignancy reports, 2008, Volume: 3, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide	2008
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells Asian Pacific journal of cancer prevention : APJCP, 2018, Apr-27, Volume: 19, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Oxides; Thalidomide; U937 Cells; Vascular Endothelial Growth Factors	2018